早期乳腺癌筛查及其与HER2阳性、病理分级和N分期的相关性。

in early breast cancer screening and correlation with HER2 positivity, pathological grade and N stage.

作者信息

Zhang Zijing, Wang Hongying, Jin Yiting, Zhou Jian, Chu Chengyu, Tang Feng, Zou Liping, Zou Qiang

机构信息

Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.

Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China.

出版信息

Biomark Med. 2023 Jun;17(12):553-562. doi: 10.2217/bmm-2023-0130. Epub 2023 Oct 10.

DOI:10.2217/bmm-2023-0130

PMID:37814985

Abstract

This study was designed to explore dysregulation and its correlation with clinical characteristics among ductal carcinoma (DCIS), DCIS with microinvasion (DCIS-MI) and invasive breast cancer (IBC) patients. KRT15 from lesion samples of 50 DCIS patients, 48 DCIS-MI patients and 50 IBC patients was detected by immunohistochemistry. discriminated IBC patients from DCIS patients (area under the curve [AUC] = 0.895; 95% CI = 0.836-0.954) and DCIS-MI patients (AUC = 0.707; 95% CI = 0.606-0.808). In DCIS patients, was negatively correlated with pathological grade (p = 0.015). In DCIS-MI patients, was positively related to estrogen receptor positivity but negatively associated with Ki-67 (both p < 0.05). In IBC patients, was negatively linked to HER2 positivity, histological grade, N stage and tumor node metastasis stage (all p < 0.05). assessment may help with early breast cancer screening.

摘要

本研究旨在探讨导管原位癌（DCIS）、微浸润性导管原位癌（DCIS-MI）和浸润性乳腺癌（IBC）患者的失调情况及其与临床特征的相关性。通过免疫组织化学检测了50例DCIS患者、48例DCIS-MI患者和50例IBC患者病变样本中的KRT15。其可将IBC患者与DCIS患者区分开（曲线下面积[AUC]=0.895；95%可信区间[CI]=0.836-0.954）以及与DCIS-MI患者区分开（AUC=0.707；95%CI=0.606-0.808）。在DCIS患者中，其与病理分级呈负相关（p=0.015）。在DCIS-MI患者中，其与雌激素受体阳性呈正相关，但与Ki-67呈负相关（均p<0.05）。在IBC患者中，其与HER2阳性、组织学分级、N分期和肿瘤淋巴结转移分期呈负相关（均p<0.05）。该评估可能有助于早期乳腺癌筛查。